Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 2, 2004, Pages 454-459

  Ben Josef, Edgar ^a,b   Shields, Anthony F ^a   Vaishampayan, Ulka ^a   Vaitkevicius, Vainutis ^a   El Rayes, Basil F ^a   McDermott, Patrick ^a   Burmeister, Jay ^a   Bossenberger, Todd ^a   Philip, Philip A ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Capecitabine; IMRT; Pancreatic cancer; Radiosensitization

Indexed keywords

CARCINOGENS; CHEMOTHERAPY; DOSIMETRY; RADIOTHERAPY; TOXICITY; TUMORS;

INTENSITY-MODULATED RADIOTHERAPY (IMRT); SURVIVAL RATES;

ONCOLOGY;

CAPECITABINE; CELECOXIB; FLUOROURACIL; GEMCITABINE;

ADD ON THERAPY; ADENOCARCINOMA; ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COLLIMATOR; COMPUTER SYSTEM; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; EVALUATION; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE; LYMPHATIC DRAINAGE; NAUSEA; NEUTROPENIA; PANCREAS CARCINOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; RETROSPECTIVE STUDY; STOMACH ULCER; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME; VOMITING; WEIGHT REDUCTION;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; HUMANS; MIDDLE AGED; PANCREATIC NEOPLASMS; PRODRUGS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES;

EID: 2442535083     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.11.019     Document Type: Article

References (23)

1. Cancer facts and figures 2003. The American Cancer Society, 2003
2. Nitecki S.S., Sarr M.G., Colby T.V., et al. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg. 221:1995;59-66
3. Gudjonsson B. Cancer of the pancreas 50 years of surgery. Cancer. 60:1987;2284-2303
4. Yeo C.J., Cameron J.L., Lillemoe K.D., et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. Two hundred and one patients. Ann Surg. 221:1995;721-733
5. Evans D.B., Abbruzzese J.L., Rich T.A. Cancer of the Pancreas. DeVita V., Hellman S., Rosenberg S.A. Cancer: Principles and practice of oncology. 5th ed:1997;1059-1060 Lippincott-Raven Publishers, Philadelphia
6. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 59:1987;2006-2010
7. Neoptolemos J.P., Dunn J.A., Stocken D.D., et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer A randomised controlled trial. Lancet. 358:2001;1576-1585
8. Klinkenbijl J.H., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 230:1999;776-782
9. Miwa M., Ura M., Nishida M., et al. Design of a novel oral fuoropyrimidine carbamate, capecitabine, which generates 5-fuorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 34:1998;1274-1281
10. Schuller J., Cassidy J., Dumont B.R., et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 45:2000;291-297
11. Sawada N., Ishikawa T., Sekiguchi F., Tanaka Y., Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 5:1999;2948-2953
12. Vaishampayan U.N., Ben-Josef E., Philip P.A., et al. A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. Int J Radiat Oncol Biol Phys. 53:2002;675-679
13. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481
14. Eisbruch A., Foote R.L., O'Sullivan B., Beitler J.J., Vikram B. Intensity-modulated radiation therapy for head and neck cancer Emphasis on the selection and delineation of the targets. Semin Radiat Oncol. 12:2002;238-249
15. Zelefsky M.J., Fuks Z., Leibel S.A. Intensity-modulated radiation therapy for prostate cancer. Semin Radiat Oncol. 12:2002;229-237
16. Landry J.C., Yang G.Y., Ting J.Y., et al. Treatment of pancreatic cancer tumors with intensity-modulated radiation therapy (IMRT) using the volume at risk approach (VARA) Employing dose-volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicity. Med Dosim. 27:2002;121-129
17. O'Connell M.J., Martenson J.A., Wieand H.S., et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 331:1994;502-507
18. Dunst J., Reese T., Sutter T., et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol. 20:2002;3983-3991
19. Kim J.S., Kim J.S., Cho M.J., Song K.S., Yoon W.H. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 54:2002;403-408
20. Ishii H., Okada S., Tokuuye K., et al. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer. 79:1997;1516-1520
21. Boz G., De Paoli A., Innocente R., et al. Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma. Int J Radiat Oncol Biol Phys. 51:2001;736-740
22. McGinn C.J., Zalupski M.M., Shureiqi I., et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 19:2001;4202-4208
23. Crane C.H., Antolak J.A., Rosen I.I., et al. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer. 30:2001;123-132